Cost-effectiveness Analysis on Salmeterol/Fluticasone Compound vs.Budesonide in the Treatment of Asthma
- VernacularTitle:沙美特罗/氟替卡松复合干粉吸入剂对照布地奈德干粉吸入剂治疗哮喘的成本-效果分析
- Author:
Li YANG
- Publication Type:Journal Article
- Keywords:
Salmeterol/fluticasone;
Budesonide;
Asthma;
Cost-effectiveness analysis
- From:
China Pharmacy
2005;0(16):-
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the cost-effectiveness of salmeterol/fluticasone compound(SFC)and budesonide(BUD)in the treatment of asthma.METHODS:A multicenter randomized controlled clinical trial was performed on386asthma cases,who were administered with SFC50/100?g bid or BUD400?g bid,data on which were retrospectively collected and then the cost-effectiveness analysis was conducted,the effectiveness was measured in terms of successfully-treated weeks,symptom-free days and uninvolved days;The direct healthcare cost was adopted as the cost index.RESULTS:The average daily medical cost of the SFC treatment group(RMB:15.6yuan)was a little bit higher than that of the BUD control group(RMB:13.8yuan),but the costs of every successfully-treated week,every symptom-free day and every uninvolved day for SFC group were166.5yuan,33.4yuan and41.2yuan,respectively,which were all lower than those of the BUD group(which were188.6yuan,50.6yuan and66.1yuan,respectively);Incremental cost-effectiveness ratios for every successful?ly-treated week,per symptom-free day and per uninvolved day for the SFC group were88.7yuan,9.4yuan and10.8yuan,respectively vs.the BUD group.CONCLUSION:The results show that the cost-effectiveness of SFC50/100?g bid is supe?rior to BUD400?g bid in the treatment of asthma.
